Mirabegron Zentiva

Mirabegron, the active ingredient in Mirabegron Zentiva, is a β3‑adrenergic receptor agonist presented as an oral tablet for oral use. It treats overactive bladder symptoms such as urinary urgency, frequency and incontinence in adult patients by relaxing the detrusor muscle and increasing bladder capacity.

GNH USA supplies Mirabegron Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirabegron is indicated for conditions within the overactive bladder spectrum, where it helps control urinary symptoms.

- Overactive bladder: reduces urgency episodes and increases bladder storage capacity. - Urinary urgency: lessens the sudden need to void, improving daily activities. - Urinary frequency: decreases the number of daytime voids, enhancing quality of life. - Urge urinary incontinence: improves continence by reducing involuntary bladder contractions.

Like all medicines, Mirabegron may be associated with adverse reactions that vary in frequency and severity.

Common Side Effects: - Dry mouth - Increased blood pressure - Nasopharyngitis - Headache

Serious or Rare Side Effects: - Severe hypertension - Urinary retention - Angle‑closure glaucoma

When prescribing Mirabegron, clinicians should consider several safety and handling precautions.

- Blood pressure monitoring: check baseline and periodically during therapy. - Cardiovascular disease: use cautiously in patients with uncontrolled hypertension or heart failure. - Drug interactions: review concomitant medications that affect adrenergic pathways. - Renal or hepatic impairment: dose adjustment may be required based on clinical judgment. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Mirabegron can affect the plasma concentrations of other drugs, requiring attention to potential interactions.

Major Interactions (Avoid): - Metoprolol: may reduce beta‑blocker efficacy, leading to increased heart rate. - CYP2D6 substrates (e.g., desipramine): plasma levels may rise, increasing toxicity risk.

Moderate Interactions (Monitor Closely): - Anticholinergics: additive effect on urinary retention. - Diuretics: may enhance hypotensive effect. - Warfarin: monitor INR as interaction potential exists.